The Medicines Company

The Medicines Company is a global pharmaceutical company focused on advancing the treatment of critically ill patients by delivering innovative, cost-effective medications to the global hospital market. It has three marketed products: ANGIOMAX (bivalirudin), Cleviprex (clevidipine butyrate) injectable emulsion, and argatroban injection. It also has a development pipeline for acute and intensive care products, which includes three late-stage development candidates (cangrelor, oritavancin, and MDCO-157) and two early-stage development candidates (MDCO-2010 and MDCO-216).